Published in Cancer Weekly, June 19th, 2001
In a Phase II, multinational clinical trial, the drug, ABT-627, delayed progression of advanced prostate cancer with few side effects in men no longer responding to hormone therapy. Results of the study were announced at the American Urological Association annual meeting in Anaheim, California, on June 4, 2001.
Current treatment options for patients who have failed hormone therapy and whose prostate cancer is progressing and spreading to other parts of the body are...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.